Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Giollo

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
The Journal of Rheumatology|December 16, 2024
Nintedanib in Rheumatoid Arthritis-Related Interstitial Lung Disease: Real-World Safety Profile and Risk of Side Effects and DiscontinuationMarco Sebastiani, Gemma Lepri, Claudia Iannone, et al.
Clinical and Experimental Rheumatology|May 19, 2017
Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registriesVeronica Codullo, Florenzo Iannone, Luigi Sinigaglia, et al.
Clinical Rheumatology|July 16, 2016
Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function abilityFlorenzo Iannone, Lugi Sinigaglia, Ennio Giulio Favalli, et al.
Swiss Medical Weekly|July 20, 2021
The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohortJasmin Hernández, Suzana Jordan, Rucsandra Dobrota, et al.
Frontiers in Pharmacology|May 15, 2026
Real-world clinical experience with upadacitinib in a cohort of Italian patients with axial spondyloarthritisRoberta Ramonda, Mariagrazia Lorenzin, Antonio Carletto, et al.
Clinical and Experimental Rheumatology|October 6, 2022
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for RheumatologyAndreina Manfredi, Giulia Cassone, Raffaella Izzo, et al.
Rheumatology (Oxford, England)|January 29, 2025
A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysisHilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, et al.
Journal of Scleroderma and Related Disorders|September 25, 2023
Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessmentCosimo Bruni, Maya H Buch, Aleksandra Djokovic, et al.
Rheumatology Advances in Practice|March 22, 2024
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaireElena Treppo, Miriam Isola, Maria De Martino, et al.
Annals of the Rheumatic Diseases|May 15, 2023
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patientsSara Monti, Alessandra Milanesi, Catherine Klersy, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
The Journal of Rheumatology|December 16, 2024
Nintedanib in Rheumatoid Arthritis-Related Interstitial Lung Disease: Real-World Safety Profile and Risk of Side Effects and DiscontinuationMarco Sebastiani, Gemma Lepri, Claudia Iannone, et al.
Clinical and Experimental Rheumatology|May 19, 2017
Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registriesVeronica Codullo, Florenzo Iannone, Luigi Sinigaglia, et al.
Clinical Rheumatology|July 16, 2016
Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function abilityFlorenzo Iannone, Lugi Sinigaglia, Ennio Giulio Favalli, et al.
Swiss Medical Weekly|July 20, 2021
The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohortJasmin Hernández, Suzana Jordan, Rucsandra Dobrota, et al.
Frontiers in Pharmacology|May 15, 2026
Real-world clinical experience with upadacitinib in a cohort of Italian patients with axial spondyloarthritisRoberta Ramonda, Mariagrazia Lorenzin, Antonio Carletto, et al.
Clinical and Experimental Rheumatology|October 6, 2022
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for RheumatologyAndreina Manfredi, Giulia Cassone, Raffaella Izzo, et al.
Rheumatology (Oxford, England)|January 29, 2025
A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysisHilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, et al.
Journal of Scleroderma and Related Disorders|September 25, 2023
Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessmentCosimo Bruni, Maya H Buch, Aleksandra Djokovic, et al.
Rheumatology Advances in Practice|March 22, 2024
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaireElena Treppo, Miriam Isola, Maria De Martino, et al.
Annals of the Rheumatic Diseases|May 15, 2023
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patientsSara Monti, Alessandra Milanesi, Catherine Klersy, et al.
Pageof 10